Congress Materials

FILTER
Select topic(s):
Content type:
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober Bruce, Puig Luis, Blauvelt Andrew et al.
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
Warren B. Richard, McInnes B. Iain, Nash Peter et al.
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
Warren B. Richard, McInnes B. Iain, Nash Peter et al.
Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Xenofon Baraliakos, Ramiro Sofia, Magrey Marina et al.
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Rudwaleit Martin, Filip Van den Bosch, Marzo-Ortega Helena et al.
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
McBride Sandra, Węgłowska Jolanta, Wolf Peter et al.
Association of EQ VAS with treatment benefits and patient-reported benefits in patients with moderate to severe psoriasis – data from the German national psoriasis registry PsoBest
Augustin Matthias, Janke M. Toni, Heidbrede Tanja et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
M. Lebwohl, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard et al.
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Blauvelt Andrew, Foley Peter, Langley G. Richard et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Magrey Marina, Marleen G.H. Van de Sande, Breban Maxime et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Magrey Marina, Marleen G.H. Van de Sande, Breban Maxime et al.
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
Garg Amit, Davis Leah, Taieb Vanessa et al.
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Blauvelt Andrew, Merola F. Joseph, Kokolakis Georgios et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Blauvelt Andrew, Conrad Curdin, Costanzo Antonio et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Blauvelt Andrew, Conrad Curdin, Costanzo Antonio et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Blauvelt Andrew, Conrad Curdin, Costanzo Antonio et al.
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Strober Bruce, Krueger G. James, Magnolo Nina et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-Week results from the Phase 3 active reference study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya et al.
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
Okubo Yukari, Tada Yayoi, Takahashi Hidetoshi et al.
Bimekizumab Efficacy and Safety in Patients with Active Psoriatic Arthritis and Psoriasis: 52-Week Results from the BE OPTIMAL and BE COMPLETE Phase 3 Randomised, Placebo-Controlled Studies
Thaci Diamant, Asahina Akihiko, Lebwohl Mark et al.
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Thaci Diamant, Puig Luis, Merola F. Joseph et al.
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
Kimball B. Alexa, Shi Y Vivian, Porter Martina et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Gottlieb B. Alice, Warren B. Richard, Augustin Matthias et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
Armstrong April, Feldman Steven, Gisondi Paolo et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index, or hyperglycemia: Results through 3 years of treatment in 5 phase 3/3b trials
Armstrong April, Feldman R. Steven, Gisondi Paolo et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Gottlieb B. Alice, Asahina Akihiko, Tsai F. Tsen et al.
Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT
Gottlieb B. Alice, Gisondi Paolo, Sator G. Paul et al.
Bimekizumab efficacy through 3 years in patients with moderate to severe plaque psoriasis: Long-term pooled analysis from BE BRIGHT
Lebwohl Mark, Strober Bruce, Foley Peter et al.
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
Han George, Gottlieb B. Alice, Armstrong April et al.
Bimekizumab impact on cardiovascular inflammation markers in moderate to severe plaque psoriasis: Results from phase 3 trials
Warren B. Richard, Langley G. Richard, Kokolakis Georgios et al.
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
Bechara G. Falk, Sayed J. Christopher, Goldberg Stephanie et al.
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Merola F. Joseph, Mease J. Philip, Deodhar Atul et al.
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
Tzellos Thrasyvoulos, Alavi Afsaneh, Kyrgidis Athanassios et al.
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
Zouboulis C Christos, Hsiao Jennifer, Reguiai Ziad et al.
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis who were Biologic DMARD-Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized
Gladman D. Dafna, Gossec Laure, M. Elaine Husni et al.
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Morita Akimichi, Merola F. Joseph, Coates C. Laura et al.
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
Hessel H. van der Zee, Kirby Brian, Bechara G. Falk et al.
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Umezawa Yoshinori, Merola F. Joseph, Coates C. Laura et al.
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Dubreuil Maureen, Gaffney Karl, Kay Jonathan et al.
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Augustin Matthias, Cather Jennifer, Papp A. Kim et al.
Bimekizumab improves key patient-reported symptoms of axial spondyloarthritis including spinal pain and fatigue: Results from two phase 3 studies
Mease J. Philip, Deodhar Atul, Dougados Maxime et al.
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Merola F. Joseph, Xenofon Baraliakos, Thaci Diamant et al.
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
Kirby S. Joslyn, Daveluy Steven, Pinter Andreas et al.
Bimekizumab in patients with moderate to severe plaque psoriasis: Analysis of mental health and associated disorders
Blauvelt Andrew, Armstrong April, Merola F. Joseph et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis who were Responders at Week 16: Results from a Phase 3, Active Reference Study
Tillett William, Merola F. Joseph, Tanaka Yoshiya et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study
Tillett William, Merola F. Joseph, Tanaka Yoshiya et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
Tillett William, Merola F. Joseph, Tanaka Yoshiya et al.
Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos, Deodhar Atul, Desiree van der Heijde et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Proft Fabian, Desiree van der Heijde, Xenofon Baraliakos et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Proft Fabian, Desiree van der Heijde, Xenofon Baraliakos et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober Bruce, Puig Luis, Blauvelt Andrew et al.
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Strober Bruce, Puig Luis, Blauvelt Andrew et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober Bruce, Puig Luis, Blauvelt Andrew et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open‑label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober Bruce, Puig Luis, Blauvelt Andrew et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Xenofon Baraliakos, Navarro-Compán Victoria, Poddubnyy Denis et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Xenofon Baraliakos, Navarro-Compán Victoria, Poddubnyy Denis et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj et al.
Bimekizumab response through 3 years in patients with plaque psoriasis who stopped and re-started treatment
Costanzo Antonio, Papp Kim, C.E.M. Griffiths et al.
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Langley G. Richard, Fernandez-Peñas Pablo, Krueger James et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Warren B. Richard, Okubo Yukari, Spelman Lynda et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Thaci Diamant, Imafuku Shinichi, Gooderham Melinda et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Blauvelt Andrew, Duffin C. Kristina, Magnolo Nina et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni, Mease J. Philip, Merola F. Joseph et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni, Mease J. Philip, Merola F. Joseph et al.
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Mease J. Philip, Gladman D. Dafna, Gossec Laure et al.
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Mease J. Philip, Dougados Maxime, Dubreuil Maureen et al.
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and its Open-Label Extension up to 1 Year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis
Gossec Laure, Coates C. Laura, Orbai Ana‐Maria et al.
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Merola F. Joseph, Gottlieb B. Alice, Ink Barbara et al.
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Merola F. Joseph, Thaci Diamant, Ink Barbara et al.
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Gottlieb B. Alice, Merola F. Joseph, Ink Barbara et al.
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
J. F. Merola, C. Conrad, P. Foley et al.
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Eyerich Kilian, Gottlieb B. Alice, Piaserico Stefano et al.
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Gladman D. Dafna, Coates C. Laura, Maarten de Wit et al.
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos, Machado M. Pedro, Bauer Lars et al.
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Ogdie R. Alexis, Song Chao, Middaugh Nicole et al.
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
Ogdie R. Alexis, Song Chao, Middaugh Nicole et al.
Early responders with zilucoplan: An interim analysis of RAISE-XT in patients with generalized myasthenia gravis
Freimer Miriam, M. Isabel Leite, Vu Tuan et al.
Effect of zilucoplan on disease fluctuation in patients with generalized myasthenia gravis in the Phase 3 RAISE study
Genge Angela, Hewamadduma Channa, Hussain Yessar et al.
Effect of zilucoplan on fatigue in generalized myasthenia gravis in the Phase 3 RAISE and RAISE-XT studies
Weiss D. Michael, Freimer Miriam, Maniaol Angelina et al.
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Haroon Nigil, Baskurt Zeynep, Chim Tina et al.
Efficacy of repeated cycles of rozanolixizumab treatment in subgroups of patients with generalized myasthenia gravis: A pooled analysis of a Phase 3 study and two Phase 3 open-label extension studies
Pascuzzi M. Robert, Mantegazza Renato, Drużdż Artur et al.
Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis
Gossec Laure, Coates C. Laura, Orbai Ana-Maria et al.
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
Zouboulis C. Christos, Kirby S. Joslyn, Tzellos Thrasyvoulos et al.
Impact of the CIMplicity® Patient Support Program on Persistence to Certolizumab Pegol Treatment: A Retrospective Cohort Analysis of Claims Data in the United States
Near Aimee, Jaganathan Srihari, Song Chao et al.
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Pinter Andreas, Augustin Matthias, Pariser David et al.
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
Deodhar Atul, Navarro-Compán Victoria, Poddubnyy Denis et al.
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Deodhar Atul, Navarro-Compán Victoria, Poddubnyy Denis et al.
Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
Mease J. Philip, Poddubnyy Denis, Orbai Ana-Maria et al.
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
Vu Tuan, Grosskreutz Julian, Gayfieva Maryam et al.
Looking beyond the numbers: Interpreting patient experience of rozanolixizumab in generalized myasthenia gravis from the MycarinG clinical trial
Regnault Antoine, Hareendran Asha, Morel Thomas et al.
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Rudwaleit Martin, Brown A. Matthew, Floris Alexander van Gaalen et al.
Management and treatment patterns in psoriasis and psoriatic arthritis
Gharib Rola, Bénard Marc, Mohrova Zuzana et al.
MG-ADL and QMG scores over time in patients with generalized myasthenia gravis: Post-hoc analysis of MycarinG and open-label studies
Bril Vera, Grosskreutz Julian, Vu Tuan et al.
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
Cutcutache Ioana, Rastrick Joe, Ferecsko Alex et al.
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
Ingram R. John, Sayed Christopher, Jacobs-Lee Rickie et al.
Patient-reported outcomes during repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis in the Phase 3 MycarinG and open-label extension studies
Habib A. Ali, Kaminski J. Henry, Vissing John et al.
Patients with psoriatic arthritis at biologic therapy switch: The CorEvitas psoriasis registry
Mease J. Philip, Jones Eric, Sima Adam et al.
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry
Mease J. Philip, Jones Eric, Sima Adam et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Nicolaes Joeri, Tselenti Evi, Aouad Theodore et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Nicolaes Joeri, Tselenti Evi, Aouad Theodore et al.
Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential
Asadullah Khusru, M.C. Fargnoli, De Simone et al.
Real-world data on the use of certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study
Warren B. Richard, Korge Bernhard, Sarro V. David et al.
Real-world patient characteristics and prior treatment history of bimekizumab patients in Germany
Zink Alexander, Ramond Anna, Shang Aijing et al.
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
Habib A. Ali, Sacconi Sabrina, Pascuzzi M. Robert et al.
Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies
Magrey Marina, Marleen G.H. Van de Sande, Breban Maxime et al.
Response rates with zilucoplan among patients with generalized myasthenia gravis in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
Vu Tuan, M. Isabel Leite, Mantegazza Renato et al.
Rheumatology Care Journey Among Patients with Psoriatic Arthritis or Axial Spondyloarthritis in the United States
Joshi Reeti, Song Chao, Beaty Silky et al.
Risk of myasthenia gravis exacerbation and level of healthcare resource utilization by Myasthenia Gravis Activities of Daily Living score
Ting Angela, Park Minjee, Sangha Oshin et al.
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Gottlieb B. Alice, Maul Julia-Tatjana, Spelman Lynda et al.
Social determinants of health are associated with suboptimal treatment among individuals with myasthenia gravis
Thompson Judith, Zhang Bo, Liberman N. Joshua et al.
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Puig Luis, Gisondi Paolo, Pinter Andreas et al.
Subcutaneous rozanolixizumab in pediatric patients with generalized myasthenia gravis: Clinical study design
Brandsema John, Kostera-Pruszczyk Anna, Addy Ibironke et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Coates C. Laura, Landewé B.M. Robert, McInnes B. Iain et al.
Temporal impact of infection-related treatment emergent adverse events on patient-reported outcomes in patients with moderate to severe psoriasis – analysis of the German national registry PsoBest
Augustin Matthias, Janke M. Toni, Heidbrede Tanja et al.
Treatment history and symptom severity in patients with moderate to severe plaque psoriasis being initiated on bimekizumab: Use during the 1st year of routine clinical practice
Asadullah Khusru, Korge Bernhard, Pinter Andreas et al.
Treatment Journey of Patients with Non-Radiographic Axial Spondyloarthritis in a US Rheumatology Office Setting: A Retrospective Chart Review
Low Robert, Hopson Sari, Beaty Silky et al.
Understanding the Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
Kuhn Kristine et al.
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment Over 52 Weeks: Results from Two Phase 3 Studies
Rudwaleit Martin, Navarro-Compán Victoria, Deodhar Atul et al.
Zilucoplan in pediatric patients with acetylcholine receptor autoantibody positive generalized myasthenia gravis: ziMyG (MG0014) and ziMyG + (MG0015) clinical study designs
Anna Kostera Pruszczyk, Addy Ibironke, Cleverly Ann et al.